Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Go back to Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide| PALATIN TECHNOLOGIES, Inc. (NASDAQ: PTN) | Delayed: 10.47 +0.10 (0.96%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.37 | 52 Week High | $0.86 | |||
| Open | $10.60 | 52 Week Low | $0.36 | |||
| Day High | $10.93 | P/E | N/A | |||
| Day Low | $9.26 | EPS | $-0.16 | |||
| Volume | 58,516 | |||||
